Douglas R. Lowy

Douglas R. Lowy, M.D., serves as Chief of the Laboratory of Cellular Oncology and Principal Deputy Director of the National Cancer Institute (NCI), with a career spanning over four decades in tumor virology and cancer signaling research. His work focuses on human papillomavirus (HPV) biology and tumor suppressor gene mechanisms.

• Affiliation: National Cancer Institute, NIH
• Roles: NIH Distinguished Investigator, Principal Deputy Director (2010–present), Acting Director (multiple terms including 2023)

Education:

• M.D. from New York University School of Medicine (1968)
• Internal Medicine Residency at Stanford University
• Dermatology Fellowship at Yale University

Research Interests encompass:

• HPV molecular biology and vaccine development
• DLC1 tumor suppressor structure and function
• Rho GTPase signaling in cancer
• Cervical cancer prevention strategies

Article Trends highlight translational virology, cancer immunology, and tumor suppressor mechanisms. His recent work explores:

• YAP signaling interactions with DLC1
• Kinase regulation of Rho-GAP activity
• HPV capsid tumor tropism
• Next-generation vaccine delivery systems

Scientific Awards include:

• Lasker-DeBakey Clinical Medical Research Award (2017)
• National Medal of Technology & Innovation (2012)
• Szent-Györgyi Prize (2018)
• Service to America Medal (2007)

He has collaborated with institutions including Johns Hopkins University, Broad Institute, and University of Liverpool. His laboratory team includes staff scientists Dunrui Wang, Xiaolan Qian, and Brajendra Tripathi.